Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Published:2016-11 Issue:11 Volume:17 Page:1543-1557
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kerr Rachel S,Love Sharon,Segelov Eva,Johnstone Elaine,Falcon Beverly,Hewett Peter,Weaver Andrew,Church David,Scudder Claire,Pearson Sarah,Julier Patrick,Pezzella Francesco,Tomlinson Ian,Domingo Enric,Kerr David J

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. QUASAR: a randomised study of adjuvant chemotherapy versus observation including 3239 colorectal cancer patients QUASAR Collaborative Group;Gray;Lancet,2007

2. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;Andre;J Clin Oncol,2009

3. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial;Schmoll;J Clin Oncol,2015

4. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses;Yothers;J Clin Oncol,2011

5. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is Risk-Stratifying Patients with Colorectal Cancer Using a Deep Learning-Based Prognostic Biomarker Cost-Effective?;PharmacoEconomics;2024-04-07

2. Improved Risk-Stratification Scheme for Mismatch-Repair Proficient Stage II Colorectal Cancers Using the Digital Pathology Biomarker QuantCRC;Clinical Cancer Research;2024-02-29

3. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis;The Lancet Oncology;2024-02

4. Neoadjuvant chemotherapy for early-stage colon cancer;Cancer Treatment Reviews;2024-02

5. Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer;Proceedings of the National Academy of Sciences;2024-01-30